1Nagai S,Izumi T.Pulmonary sarcoidosis: population differences and pathophysiology[].Southampton Medical Journal.1995
2Dubaniewicz A,Szczerkowska Z.HLA-A, B, C antigens in pulmonary sarcoidosis in polish population[].Archivum Immunologiae et Therapiae Experimentalis.1999
3Ohmichi M,Yamada G,Hiraga Y.Corticosteroid treatment in pulmonary sarcoidosis[].Japanese Journal of Clinical Medicine.1994
4Padilla ML,Schilero GJ,Teirstein AS.Sarcoidosis and transplantation[].Sarcoidosis Vasc Diffuse Lung Dis.1997
5Statement on sarcoidosis. Joint Statement of the American Thoracic Society(ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG)adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med, 1999, 160:736- 755.
6Mossman BT, Mason R, McDonald JA, et al. Advances in molecular genetics, transgenic models, and gene therapy for the study of pulmonary diseases. Am J Respir Crit Care Med, 1995,151 : 2065-2069.
7Perng RP, Chou KT, Chu H, et al. Familial sarcoidosis in Taiwan. J Formos Med Assoc,2007,106:499-503.
8Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/ WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis, 1999,16 : 149-173.
